Clinical trial · Interventional
Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI
Pilot Differentiation of Bone Sarcomas and Osteomyelitis With Ferumoxytol-Enhanced MRI
NCT01336803CI-TRIAL-00072564OsteosarcomacompletedPhase 2Results postedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This pilot trial studies the differentiation of bone sarcomas and osteomyelitis with ferumoxytol-enhanced magnetic resonance imaging (MRI). Imaging procedures that allow doctors to more accurately differentiate between malignant bone sarcomas and osteomyelitis may help in diagnosing patients correctly and may result in more timely treatment.
Conditions
Conditions (8)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Bone Cancer | Malignant Bone Neoplasm | ALIAS | 0.90 |
| Bone Necrosis | — | UNRESOLVED | — |
| Bone Sarcoma | Bone Sarcoma | ONTOLOGY_EXACT | 0.98 |
| Chondrosarcoma | Chondrosarcoma | ONTOLOGY_EXACT | 0.98 |
| Ewing's Sarcoma | Ewing Sarcoma | ALIAS | 0.90 |
| Osteomyelitis | — | UNRESOLVED | — |
| Osteosarcoma | Osteosarcoma | ONTOLOGY_EXACT | 0.90 |
| Rhabdomyosarcoma | Rhabdomyosarcoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Feraheme | Drug | — | UNRESOLVED |
| Magnetic Resonance Imaging (MRI) scan | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Feraheme
- description
- Intravenous injection of Feraheme, 5 mg Fe/kg
- interventionNames
- Drug: Feraheme
- Procedure: Magnetic Resonance Imaging (MRI) scan
Primary outcomes (1)
- measure
- T2* Relaxation Time of Bone Sarcomas and Osteomyelitis Subjects
- timeFrame
- 24 hours
- description
- Differentiation of bone sarcomas and osteomyelitis with ferumoxytol-enhanced magnetic resonance imaging (MRI) was assessed as the difference of mean T2 \* relaxation time of bone sarcoma and osteomyelitis subjects. The outcome is reported as the difference of the mean T2 \* values, with standard deviation.
Secondary outcomes (4)
- measure
- Differentiation of Bone Sarcomas Pre-ferumoxytol and Post-ferumoxytol Contrast
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 10 Years
- Maximum age
- 21 Years
Show eligibility criteria text
INCLUSION CRITERIA * Age 10 to 21 years * Suspected or confirmed diagnosis of a bone sarcoma or osteomyelitis * Informed consent with assent as appropriate. EXCLUSION CRITERIA * Contraindication to MRI * Presence of metal implants * Need for sedation or anesthesia * Claustrophobia * Hemosiderosis or hemochromatosis * History of allergic reactions to similar compounds will be obtained and patients with positive history of allergic reactions will be excluded from the study * Females who are pregnancy or nursing
References
Publications (0)
Data not yet available
No reference posted for this study.